PD-1 blockade conferred benefit to certain women with surgically resectable endometrial cancer, findings presented at Society ...
Neoadjuvant nivolumab has demonstrated efficacy in patients with mismatch repair-deficient, surgically resectable endometrial cancer.
Xeris Biopharma Holdings, Inc. , a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback